[In reference to "Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]. (2017). Farmeconomia. Health Economics and Therapeutic Pathways, 18(1). https://doi.org/10.7175/fe.v18i1.1315